Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

From The Editors: October 2021

TOP - October 2021 Vol 14, No 6 | Biosimilars - From the Editors, Biosimilars
Patrick J. Medina, PharmD, BCOP
Medical Science Liaison
Medical Affairs, GlaxoSmithKline
Collegeville, PA
Adjunct Professor of Pharmacy
University of Oklahoma College of Pharmacy
Steven Stricker, PharmD, MS, BCOP
Assistant Professor of Pharmacy Practice
McWhorter School of Pharmacy
Samford University
Birmingham, AL

In recent years, biologics have increasingly been used for the treatment and supportive care of patients with various serious illnesses, including cancer. These agents, which include therapeutic proteins and monoclonal antibodies, are large complex molecules typically manufactured in genetically engineered organisms. Although biologics have been shown to be very effective in the treatment of many types of malignancies, they are also among the most expensive oncology drugs on the market in the United States. The high price tag associated with biologics can be attributed to several factors, including a costly manufacturing process and the large investment in research and development necessary to take them through clinical trials and the FDA approval process.

The cost of biologics, coupled with recent patent expirations of several of these agents, has led to the development and approval of several biosimilars for the treatment of cancer and other conditions. A biosimilar is a biologic that is highly similar to, and has no clinically meaningful differences from, another biologic that is already approved by the FDA.

Although biosimilars have the potential to reduce healthcare costs, increase competition, and improve patient access to highly effective biologic agents, there are hurdles that must be addressed before the full potential of these agents can be realized. Perhaps one of the largest hurdles to the integration of biosimilars is the acceptance of these agents by physicians and patient consumers. To overcome this hurdle, it is essential that we close major knowledge gaps regarding the safety and efficacy of biosimilars and their successful adoption in clinical practice. These gaps include defining biologics versus biosimilars in the context of biosimilarity, understanding the approval process and the use of the “totality of evidence” approach by the FDA for biosimilar evaluation, understanding the evidence requirements

for demonstration of safety and immunogenicity of a biosimilar versus its reference product, and defining interchangeability in the context of pharmacy-level substitution.

Oncology pharmacists will play an increasingly important role in educating prescribers and patients regarding the particulars of switching from reference biologics to biosimilars. They can also answer questions and address common misconceptions regarding safety and efficacy issues that may deter the use of these agents. The purpose of this special issue of The Oncology Pharmacist (TOP) is to provide pharmacists with the information they need to take the lead in these important conversations.

We hope you will enjoy this special issue of TOP, and we invite you to visit www.TheOncologyPharmacist.com to share your feedback about this issue with us or send comments to info@TheOncologyPharmacist.com.

Related Items
From The Editors November 2022
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in From the Editors
From The Editors September 2022
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in From the Editors
From The Editors July 2022
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in From the Editors
From The Editors: May 2022
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in From the Editors
HHS OIG Report Demonstrates Need for Changes to Part D to Increase Biosimilar Use
Steven Selde
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in Biosimilars
From The Editors March 2022
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in From the Editors
From The Editors
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in From the Editors
From The Editors: November 2021
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in From the Editors
Survey of Oncologists Reveals Ongoing Misconceptions and Concerns Regarding Biosimilars
Charlie Dawson
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in ASCO Quality Care Symposium, Biosimilars
Latest AAM Report Shows Generic and Biosimilar Drugs Saved US Healthcare System $338 Million in 2020
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in Value-Based Care, Biosimilars
Last modified: November 8, 2021